vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $52.3M, roughly 1.8× ACME UNITED CORP). Vericel Corp runs the higher net margin — 25.0% vs 1.9%, a 23.1% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 13.8%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -2.9%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
ACU vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $92.9M |
| Net Profit | $985.0K | $23.2M |
| Gross Margin | 39.7% | 78.7% |
| Operating Margin | 3.3% | 24.1% |
| Net Margin | 1.9% | 25.0% |
| Revenue YoY | 13.8% | 23.3% |
| Net Profit YoY | -40.4% | 17.3% |
| EPS (diluted) | $0.24 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $92.9M | ||
| Q3 25 | $49.1M | $67.5M | ||
| Q2 25 | $54.0M | $63.2M | ||
| Q1 25 | $46.0M | $52.6M | ||
| Q4 24 | $45.9M | $75.4M | ||
| Q3 24 | $48.2M | $57.9M | ||
| Q2 24 | $55.4M | $52.7M |
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | $23.2M | ||
| Q3 25 | $1.9M | $5.1M | ||
| Q2 25 | $4.8M | $-553.0K | ||
| Q1 25 | $1.7M | $-11.2M | ||
| Q4 24 | $1.7M | $19.8M | ||
| Q3 24 | $2.2M | $-901.0K | ||
| Q2 24 | $4.5M | $-4.7M |
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | 78.7% | ||
| Q3 25 | 39.1% | 73.5% | ||
| Q2 25 | 41.0% | 73.7% | ||
| Q1 25 | 39.0% | 69.0% | ||
| Q4 24 | 38.7% | 77.6% | ||
| Q3 24 | 38.5% | 71.9% | ||
| Q2 24 | 40.8% | 69.5% |
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | 24.1% | ||
| Q3 25 | 6.1% | 5.1% | ||
| Q2 25 | 11.8% | -3.2% | ||
| Q1 25 | 5.3% | -24.3% | ||
| Q4 24 | 5.0% | 24.5% | ||
| Q3 24 | 6.1% | -4.3% | ||
| Q2 24 | 11.5% | -11.5% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | 25.0% | ||
| Q3 25 | 3.9% | 7.5% | ||
| Q2 25 | 8.8% | -0.9% | ||
| Q1 25 | 3.6% | -21.4% | ||
| Q4 24 | 3.7% | 26.3% | ||
| Q3 24 | 4.6% | -1.6% | ||
| Q2 24 | 8.0% | -8.9% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $0.46 | ||
| Q3 25 | $0.46 | $0.10 | ||
| Q2 25 | $1.16 | $-0.01 | ||
| Q1 25 | $0.41 | $-0.23 | ||
| Q4 24 | $0.43 | $0.40 | ||
| Q3 24 | $0.54 | $-0.02 | ||
| Q2 24 | $1.09 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $137.5M |
| Total DebtLower is stronger | $33.0M | — |
| Stockholders' EquityBook value | $116.7M | $354.6M |
| Total Assets | $195.2M | $488.0M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $137.5M | ||
| Q3 25 | $5.1M | $135.4M | ||
| Q2 25 | $3.6M | $116.9M | ||
| Q1 25 | $3.4M | $112.9M | ||
| Q4 24 | $6.4M | $116.2M | ||
| Q3 24 | $5.7M | $101.7M | ||
| Q2 24 | $3.8M | $102.5M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $354.6M | ||
| Q3 25 | $115.8M | $321.9M | ||
| Q2 25 | $113.7M | $306.8M | ||
| Q1 25 | $108.3M | $295.5M | ||
| Q4 24 | $107.0M | $292.0M | ||
| Q3 24 | $106.3M | $257.5M | ||
| Q2 24 | $104.0M | $243.0M |
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $488.0M | ||
| Q3 25 | $173.0M | $453.3M | ||
| Q2 25 | $170.9M | $435.6M | ||
| Q1 25 | $163.0M | $424.6M | ||
| Q4 24 | $162.2M | $432.7M | ||
| Q3 24 | $165.5M | $390.4M | ||
| Q2 24 | $173.5M | $376.8M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $15.0M | ||
| Q3 25 | $7.1M | $22.1M | ||
| Q2 25 | $6.3M | $8.2M | ||
| Q1 25 | $-3.3M | $6.6M | ||
| Q4 24 | $6.4M | $22.2M | ||
| Q3 24 | $8.9M | $10.2M | ||
| Q2 24 | $6.9M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | $12.8M | ||
| Q3 25 | $301.0K | $19.5M | ||
| Q2 25 | $4.7M | $81.0K | ||
| Q1 25 | $-4.7M | $-7.6M | ||
| Q4 24 | $4.7M | $8.5M | ||
| Q3 24 | $7.5M | $-9.2M | ||
| Q2 24 | $4.4M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 13.8% | ||
| Q3 25 | 0.6% | 28.8% | ||
| Q2 25 | 8.7% | 0.1% | ||
| Q1 25 | -10.2% | -14.5% | ||
| Q4 24 | 10.2% | 11.2% | ||
| Q3 24 | 15.6% | -15.9% | ||
| Q2 24 | 8.0% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 2.4% | ||
| Q3 25 | 13.8% | 3.9% | ||
| Q2 25 | 3.0% | 12.9% | ||
| Q1 25 | 2.9% | 27.0% | ||
| Q4 24 | 3.7% | 18.3% | ||
| Q3 24 | 2.8% | 33.5% | ||
| Q2 24 | 4.5% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | 0.65× | ||
| Q3 25 | 3.72× | 4.35× | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | -2.02× | — | ||
| Q4 24 | 3.73× | 1.12× | ||
| Q3 24 | 3.99× | — | ||
| Q2 24 | 1.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACU
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
